Azilsartan Medoxomil
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension
Trial Timeline
Aug 7, 2018 → May 25, 2023
NCT ID
NCT04470817About Azilsartan Medoxomil
Azilsartan Medoxomil is a pre-clinical stage product being developed by Celltrion for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT04470817. Target conditions include Essential Hypertension.
What happened to similar drugs?
15 of 20 similar drugs in Essential Hypertension were approved
Approved (15) Terminated (2) Active (5)
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04470817 | Pre-clinical | Completed |
Competing Products
20 competing products in Essential Hypertension